Joseph M. Flynn

Oncology | Hematology | Hematology Oncology

9880 Angies Way
Suite 250
Louisville, KY 40241

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

A simple method to estimate flow restriction for dual ventilation of dissimilar patients: The BathRC model.

A simple method to estimate flow restriction for dual ventilation of dissimilar patients: The BathRC model.

Journal: PloS one

Published: May 31, 2020

Multidisciplinary approach to low-dose CT screening for lung cancer in a metropolitan community.

Multidisciplinary approach to low-dose CT screening for lung cancer in a metropolitan community.

Journal: Family practice

Published: July 06, 2019

The Correlative Strength of Objective Physical Assessment Against the ECOG Performance Status Assessment in Individuals Diagnosed With Cancer.

The Correlative Strength of Objective Physical Assessment Against the ECOG Performance Status Assessment in Individuals Diagnosed With Cancer.

Journal: Physical therapy

Published: January 28, 2019

A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.

A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.

Journal: British journal of haematology

Published: June 30, 2017

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 19, 2017

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.

Journal: Blood advances

Published: March 30, 2017

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Journal: Leukemia & lymphoma

Published: March 09, 2017

The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.

The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.

Journal: Cancer medicine

Published: September 16, 2016

Ibrutinib treatment improves T cell number and function in CLL patients.

Ibrutinib treatment improves T cell number and function in CLL patients.

Journal: The Journal of clinical investigation

Published: August 02, 2016

Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia.

Individual differences in physical symptom burden and psychological responses in individuals with chronic lymphocytic leukemia.

Journal: Annals of hematology

Published: March 20, 2016

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.

Journal: Leukemia & lymphoma

Published: January 15, 2016

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Journal: Leukemia

Published: July 23, 2015

Showing 1-12 of 51

Last Updated: 09/26/2026